Bizarre Patents
An extension member is attachable to a trailer hitch and extends away from the vehicle and is connected to a seating frame supporting a toilet seat.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7943625 | 2 thioxanthine derivatives acting as MPO-inhibitors The present invention relates to a compound according to Formula (I) wherein R1 is selected from C1-C6 alkyl, and said C1-C6 alkyl is substituted with C1... | 05/17/2011 |
| 7423041 | A1 adenosine receptor antagonists Compounds of the general formula (I) are described: wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described. ... | 09/09/2008 |
| 7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs t... | 08/05/2008 |
| 7312223 | Metabolite of xanthine Phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structure derivatives, and formulations thereof, and processes for preparing the same. ... | 12/25/2007 |
| 7268141 | Xanthine phosphodiesterase V inhibitors A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: | 09/11/2007 |
| 7247630 | Uses of tricyclic compounds Novel tricyclic compounds are disclosed having the general structure of Formulas I or II: were R1, R2 and R3 are defined in the written description of the invention. The compounds are useful for the treatment or ... | 07/24/2007 |
| 7247639 | A1 adenosine receptor antagonists The present invention provides novel adenosine receptor antagonists, more particularly, A1 adenosine receptor antagonists of formula (I). Pharmaceutical compositions comprising an A1 adenosine receptor antagonist of formula (I) and a pharmaceut... | 07/24/2007 |
| 7238706 | 4-oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitors Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation and useful for the enhancement of cognit... | 07/03/2007 |
| 7229473 | Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent Methods of preparing intravascular stents with a polymeric coating containing macrocyclic lactone (such as rapamycin or its analogs), stents and stent graphs with such coatings, and methods of treating a coronary artery with such devices. The macrocyclic lactone-bas... | 06/12/2007 |
| 7223286 | Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent Methods of preparing intravascular stents with a polymeric coating containing macrocyclic lactone (such as rapamycin or its analogs), stents and stent graphs with such coatings, and methods of treating a coronary artery with such devices. The macrocyclic lactone-bas... | 05/29/2007 |
| 7217286 | Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent Methods of preparing intravascular stents with a polymeric coating containing macrocyclic lactone (such as rapamycin or its analogs), stents and stent graphs with such coatings, and methods of treating a coronary artery with such devices. The macrocyclic lactone-bas... | 05/15/2007 |
| 7202252 | Aadenosine receptor antagonists Compounds of the general formula (I) are described: wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described. ... | 04/10/2007 |
| 7192962 | Xanthine phosphodiesterase V inhibitor polymorphs Crystalline polymorphs of 1-ethyl-3,7-dihydro-8-[(1R,2R) -(hydroxycyclopentyl)amino]-3-(2-hydroxyethyl)-7-[(3-bromo-4-methoxyphenyl)methyl]-1H-Purine-2,6-dione in Form 1 and Form 2, which exhibit x-ray powder diffraction profiles substantially the same as those show... | 03/20/2007 |
| 7135475 | Amide substituted xanthine derivatives The present invention is a 1,3,8 substituted xanthine derivative of formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are as defined in the specificat... | 11/14/2006 |
| 7122207 | High drug load acid labile pharmaceutical composition A high drug load spheronized beadlet is provided wherein said beadlet comprises about 80% to 100% by weight of an acid labile medicament, preferably didanosine, about 0% to about 10% by weight of a disintegrant, and about 0% to about 10% by weight of a binder select... | 10/17/2006 |
| 7098217 | 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands 3,7-Dihydro-purine-2,6-dione derivatives of Formula (I) are provided wherein R1, R2, R3 and R4 are herein defined for use as CRF receptor ligands in the treatment of di... | 08/29/2006 |
| 7074923 | Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof A process for preparing xanthine phosphodiesterase V inhibitors, and compounds utilized in said process. The process includes a five-step methodology for efficient synthesis of Compound 5 without intermediate purifications or separations, a dihalogenation step to sy... | 07/11/2006 |
| 7053096 | Compounds having selective hydrolytic potentials Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems. ... | 05/30/2006 |
| 6964968 | Method for the treatment or prevention of viral infection using nucleoside analogues Viral infections selected from the group consisting of herpes simplex virus, varicella zoster virus, respiratory syncytial virus and cytomegalovirus can be treated by administering to the host a therapeutically effective amount of a compound of formula I or a pharma... | 11/15/2005 |
| 6927135 | Methods of fabricating multiple sets of field effect transistors The invention includes methods of fabricating multiple sets of field effect transistors. In one implementation, an etch stop layer is formed over an insulative capping layer which is formed over a conductive gate layer formed over a substrate. The etch stop layer, t... | 08/09/2005 |
| 6878715 | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intrace... | 04/12/2005 |
| 6855736 | Molecular target of neurotoxicity The present invention relates to the fields of biology, genetics and medicine. In particular it concerns new methods for the detection, characterization and/or treatment (or management) of neuro degenerative diseases, particularly amyotrophic lateral sclerosis. ... | 02/15/2005 |
| 6780865 | Compounds having selective hydrolytic potentials Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems. The disclosed compounds have a structure of formula I: ... | 08/24/2004 |
| 6774130 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intrace... | 08/10/2004 |
| 6693106 | Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (AGE's) Pentoxifylline, pioglitazone and metformin have been found to inhibit the nonenzymatic glycation of proteins which often results in formation of advanced glycation endproducts and crosslinks. The nonenzymatic glycation and crosslinking of proteins is a pa... | 02/17/2004 |
| 6649600 | Adenosine receptor antagonists and methods of making and using the same The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be usefull in the prevention and/or treatment of n... | 11/18/2003 |
| 6608069 | Phenyl xanthine derivatives The present invention relates to novel compounds of formula (I): ##STR1## wherein Z represents a 5 or 6 membered cycloalkyl, aryl, substituted cycloalkyl, or substituted aryl, said cycloalkyl, aryl, substituted cycloalkyl or substituted aryl optionally co... | 08/19/2003 |
| 6605600 | Adenosine receptor antagonists and methods of making and using the same The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be useful in the prevention and/or treatment of nu... | 08/12/2003 |
| 6586478 | Methods and compositions for improving sleep Methods and compositions for improving sleep in individuals with sleep disorders or other conditions which interfere with normal sleep via administration of a NO-mimetic are provided.... | 07/01/2003 |
| 6558660 | Method for regulating IL-10 with IL-9, and applications thereof The invention involves the recognition of IL-9 as a molecule involved in induction of IL-10. Administration of IL-9 leads to protection against conditions where IL-10 production is warranted, such as infections by Gram negative bacteria. Examples of such ... | 05/06/2003 |
| 6486170 | Phospholipase A2 inhibitors as mediators of gene expression A signaling pathway is identified that involves the activation of phospholipase A2 and protein kinase C in human cells, which in turn confers x-ray induction of the tumor necrosis factor (TNF) gene. Inhibition of phospholipase A2 abolishes radiati... | 11/26/2002 |
| 6469017 | Method of inhibiting interleukin-12 signaling A method for blocking IL-12 signaling by administration of the following compound: ##STR1## wherein, R1 is H, CH3, sulfate, phosphate, or salt thereof; R2 is alkyl (C1-12), alkoxyalkyl (C1-11), dialko... | 10/22/2002 |
| 6423719 | Method for treating benign prostate hyperplasia A method of treating and/or preventing renal dysfunction in a patient, such as renal colic or contrast nephropathy by administering to a patient, a compound of the formula: ##STR1## is described herein. Administration of dyphylline in a sustained release ... | 07/23/2002 |
| 6420374 | Use of xanthines as immunosuppressants and to inhibit allograft reactions A family of compounds effective in suppressing lymphocyte activation is comprised of 7-(oxoalkyl)1,3-dialkyl xanthines, other than denbufylline, of the formula ##STR1## in which R1 and R2 are the same or different and are selected ... | 07/16/2002 |
| 6413976 | Compositions and method for decreasing neuropathic pain Compositions containing propentofylline, and methods for treating neuropathic pain with such compositions, are disclosed.... | 07/02/2002 |
| 6399624 | Method and composition for inhibiting post-surgical adhesions A method and compositions for reducing post-surgical adhesion formation/reformation in mammals following surgical injury to a body cavity or organs situated therein. The aqueous compositions comprising pentoxifylline and a polyoxyalkylene block copolymer ... | 06/04/2002 |
| 6372740 | 2-aryl-8-oxodihydropurine derivative, process for the producing the same, medicinal compositions containing the same, and intermediates thereof 2-Aryl-8-oxodihydropurine derivative of the following formula (I): ##STR1## wherein W is H, lower alkyl, halogen, lower alkoxy, amino, mono- or di-lower alkylamino, or substituted or unsubstituted phenyl; X is H, lower alkyl, cycloalkyl-lower alkyl, subst... | 04/16/2002 |
| 6337325 | Combined preparation for the therapy of immune diseases A combination preparation comprising a compound which has a phosphodiesterase-inhibiting action, and a compound which reduces the biologically effective intracellular Ca2+ content, is suitable for the treatment of immunological diseases.... | 01/08/2002 |
| 6329381 | Heterocyclic compounds The present invention relates to a heterocyclic compound of the following general formula (I): ##STR1## wherein X is sulfur atom, oxygen atom or --NR3 -- (R3 may form a heterocyclic ring or a substituted heterocyclic ring with R... | 12/11/2001 |
| 6316458 | Method of enhancing insulin action A category of hydroxyalkyl-substituted xanthines are useful in treating patients suffering from disorders associated with impaired glucose metabolism or impaired insulin function. Use of these compounds, for example, restores insulin responsiveness in oth... | 11/13/2001 |
